Bertolín-Boronat Carlos, Merenciano-González Héctor, Marcos-Garcés Víctor, Martínez Mas María Luz, Climent Alberola Josefa Inés, Civera José Manuel, Valls Reig María, Ruiz Hueso Marta, Castro Carmona Patricia, Perez Nerea, López-Bueno Laura, Díaz Díaz Beatriz, Miñano Martínez Isabel, Payá Rubio Alfonso, Ríos-Navarro César, de Dios Elena, Gavara Jose, Jiménez-Navarro Manuel F, Sanchis Juan, Bodi Vicente
Department of Cardiology, Hospital Clinico Universitario de Valencia, 46010 Valencia, Spain.
INCLIVA Health Research Institute, 46010 Valencia, Spain.
J Clin Med. 2025 Jun 14;14(12):4242. doi: 10.3390/jcm14124242.
A significant proportion of post-myocardial infarction (MI) patients do not reach target low-density lipoprotein cholesterol (LDL-C) levels. Suboptimal LDL-C reduction is often attributed to poor adherence to pharmacological therapy and lifestyle recommendations. : In a prospective registry of 179 post-MI patients who completed a Phase 2 Cardiac Rehabilitation Program (CRP), we evaluated the characteristics and predictors of suboptimal LDL-C reduction. Key indicators were assessed before and after CRP: adherence to the Mediterranean diet (using the PREDIMED questionnaire), weekly physical activity (via the IPAQ questionnaire), therapeutic adherence (using the Morisky-Green questionnaire), and peak oxygen consumption (VO) on exercise testing. Lipid-lowering therapy (LLT) and LDL-C were recorded prior to MI and both before and after Phase 2 CRP. At the end of Phase 2, we analyzed the difference between measured and theoretical LDL-C (basal LDL-C minus expected LDL-C reduction by LLT), which was defined as "residual difference in LDL-C" (RD-LDL-C). We analyzed the predictors of positive RD-LDL-C (lower than theoretically expected). : After CRP, 54 (30.2%) patients exhibited positive RD-LDL-C. Within this subgroup, LLT was uptitrated, and patients received more potent LLT at the conclusion of CRP (theoretical potency: 69.81 ± 7.07 vs. 66.41 ± 7.48%, = 0.005). However, they were less likely to reach the target LDL-C level <55 mg/dL (66.7% vs. 93.6%, < 0.001). Male sex (HR 17.96 [2.15, 149.92], = 0.008) and higher lipoprotein (a) levels (HR 1.02 [1.01, 1.03] per mg/dL, = 0.001) were associated with a positive RD-LDL-C. Conversely, diabetes mellitus (HR 0.17 [0.06, 0.51], = 0.002), higher corrected basal LDL-C levels (HR 0.98 [0.97, 0.99] per mg/dL, = 0.001), and supervised in-hospital training during CRP (HR 0.28 [0.09, 0.86], = 0.03) were associated with a reduced probability of positive RD-LDL-C. No association was found with adherence to the Mediterranean diet (88.1%), therapeutic adherence (89.1%), reported weekly physical activity (median 3545 [1980, 6132] metabolic equivalents per week), or change in peak VO. : More than one-third of post-MI patients demonstrated lower than expected LDL-C reduction (positive RD-LDL-C) following CRP, a finding that could not be attributed to poor adherence to pharmacological therapy or lifestyle recommendations. These findings suggest that a personalized approach to prescribing and uptitrating LLT may help achieve LDL-C targets, particularly in MI patients with healthy lifestyle habits who exhibit a lower response to LLT.
相当一部分心肌梗死(MI)后患者未达到低密度脂蛋白胆固醇(LDL-C)目标水平。LDL-C降低未达最佳效果通常归因于对药物治疗和生活方式建议的依从性差。在一项对179例完成了第二阶段心脏康复计划(CRP)的心肌梗死后患者的前瞻性登记研究中,我们评估了LDL-C降低未达最佳效果的特征和预测因素。在CRP前后评估关键指标:对地中海饮食的依从性(使用PREDIMED问卷)、每周体育活动量(通过IPAQ问卷)、治疗依从性(使用Morisky-Green问卷)以及运动测试中的峰值耗氧量(VO)。在心肌梗死之前以及第二阶段CRP之前和之后记录降脂治疗(LLT)和LDL-C。在第二阶段结束时,我们分析了测量的LDL-C与理论LDL-C(基础LDL-C减去LLT预期的LDL-C降低值)之间的差异,其被定义为“LDL-C残留差异”(RD-LDL-C)。我们分析了RD-LDL-C为阳性(低于理论预期)的预测因素。CRP后,54例(30.2%)患者表现出RD-LDL-C为阳性。在该亚组中,上调了LLT,并且患者在CRP结束时接受了更强效的LLT(理论效力:69.81±7.07%对66.41±7.48%,P = 0.005)。然而,他们达到LDL-C目标水平<55mg/dL的可能性较小(66.7%对93.6%,P<0.001)。男性(HR 17.96[2.15,149.92],P = 0.008)和较高的脂蛋白(a)水平(每mg/dL HR 1.02[1.01,1.03],P = 0.001)与RD-LDL-C为阳性相关。相反,糖尿病(HR 0.17[0.06,0.51],P = 0.002)、较高的校正基础LDL-C水平(每mg/dL HR 0.98[0.97,0.99],P = 0.001)以及CRP期间在医院的监督训练(HR 0.28[0.09,0.86],P = 0.03)与RD-LDL-C为阳性的概率降低相关。未发现与对地中海饮食的依从性(88.1%)、治疗依从性(89.1%)、报告的每周体育活动量(每周中位数3545[1980,6132]代谢当量)或峰值VO的变化有关。超过三分之一的心肌梗死后患者在CRP后表现出LDL-C降低低于预期(RD-LDL-C为阳性),这一发现不能归因于对药物治疗或生活方式建议的依从性差。这些发现表明,个性化的LLT处方和上调方法可能有助于实现LDL-C目标,特别是在对LLT反应较低但具有健康生活方式习惯的心肌梗死患者中。